Goldenwell Biotech Inc
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech Inc (GWLL) - Total Assets
Latest total assets as of June 2025: $251.29K USD
Based on the latest financial reports, Goldenwell Biotech Inc (GWLL) holds total assets worth $251.29K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Goldenwell Biotech Inc - Total Assets Trend (2019–2024)
This chart illustrates how Goldenwell Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Goldenwell Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Goldenwell Biotech Inc's total assets of $251.29K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $174.79K | 78.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Goldenwell Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Goldenwell Biotech Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, down from 100.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 78.0% of total assets.
Goldenwell Biotech Inc Competitors by Total Assets
Key competitors of Goldenwell Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
B&G Foods Inc
NYSE:BGS
|
USA | $2.94 Billion |
|
Tangrenshen Group Co Ltd
SHE:002567
|
China | CN¥17.90 Billion |
|
Shenzhen Shenbao Industrial Co Ltd
SHE:000019
|
China | CN¥7.01 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
Goldenwell Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Goldenwell Biotech Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Goldenwell Biotech Inc is currently not profitable relative to its asset base.
Goldenwell Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.90 | 167.28 | 3.44 |
| Quick Ratio | 1.19 | 21.47 | 1.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $186.94K | $ 199.20K | $ 307.40K |
Goldenwell Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Goldenwell Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5175.12 |
| Latest Market Cap to Assets Ratio | 32.12 |
| Asset Growth Rate (YoY) | -1.7% |
| Total Assets | $224.19K |
| Market Capitalization | $7.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Goldenwell Biotech Inc's assets at a significant premium ( 32.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Goldenwell Biotech Inc's assets decreased by 1.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Goldenwell Biotech Inc (2019–2024)
The table below shows the annual total assets of Goldenwell Biotech Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $224.19K | -1.69% |
| 2023-12-31 | $228.06K | -8.19% |
| 2022-12-31 | $248.40K | -46.11% |
| 2021-12-31 | $460.98K | +85.45% |
| 2020-12-31 | $248.57K | +0.80% |
| 2019-12-31 | $246.59K | -- |